MedTrace Logo

Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

NCT00241527 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 556

Last updated 2011-01-24

No results posted yet for this study

Summary

This study was a randomised, double-blind, parallel-group and placebo controlled study comparing the efficacy of esomeprazole 40 mg orally qd vs placebo and esomeprazole 20 mg orally qd vs placebo when given to patients on continuous use of NSAIDs, including COX-2 selective NSAIDs, for a treatment period of 4 weeks for relief of upper GI symptoms.

Conditions

  • NSAIDs
  • Upper GI Symptoms

Interventions

DRUG

Esomeprazole

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Nexium Medical Sciences Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-12-31
Primary Completion
2002-09-30
Completion
2002-09-30

Countries

  • United States
  • Australia
  • Canada
  • Czechia
  • Italy
  • Norway
  • Poland
  • Slovakia
  • South Africa
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00241527 on ClinicalTrials.gov